Clinical and pharmacological group: & nbsp
Nootropics
Included in the formulation
Gliatilin
capsulessolution
inwards w / m in / in
Gliatilin
capsulessolution
inwards w / m in / in
Cerepro
capsulessolution
inwards w / m in / in
Included in the list (Order of the Government of the Russian Federation No. 2782-r of 30.12.2014):ONLS
VED
АТХ:N.07.A.X.02 Choline alfoscerate
Pharmacodynamics:It is a substrate for the synthesis of phosphatidylcholine neuronal membranes and acetylcholine. It interacts mainly with the cholinergic receptors of the central nervous system. It improves cerebral blood flow, improves receptor function and plasticity of neuronal membranes, stimulates the reticular formation and metabolism in the central nervous system.
It improves concentration of attention, stimulates mental activity, improves cognitive function, eliminates apathy and emotional instability. Promotes regress of neurological symptoms after traumatic brain injuries.
Pharmacokinetics:After oral administration, up to 88% is absorbed in the gastrointestinal tract. Penetrates through the blood-brain barrier and accumulates in the brain - up to 45% of the amount in the blood plasma.
It is biotransformed to glycerophosphate and choline, which have pharmacological activity.
Elimination in the form of carbon dioxide light (up to 85%), the remaining 15% are excreted with feces and kidneys.
Indications:It is used for the treatment of chronic cerebrovascular insufficiency, Alzheimer's disease and dementia, Huntington's chorea, senile pseudomelanchia. Used for craniocerebral trauma in an acute period, as well as in the early and late recovery period after an ischemic stroke.
V.F00-F09.F00 * Dementia in Alzheimer's disease (G30 .- +)
V.F00-F09.F01 Vascular dementia
V.F00-F09.F07 Personality and behavioral disorders due to illness, damage or dysfunction of the brain
V.F00-F09.F07.2 Postcontasia syndrome
VI.G20-G26.G25.5 Other types of chorea
IX.I60-I69.I63 Cerebral infarction
XIX.S00-S09.S06 Intracranial injury
Contraindications:Acute phase of hemorrhagic stroke, individual intolerance, children under 18 years of age.
Carefully:Hypersensitivity.
Pregnancy and lactation:Recommendations for FDA - Category C. Contraindicated in pregnancy and lactation.
Dosing and Administration:Intramuscularly or intravenously, slowly 1 g per day in the morning in acute conditions, up to 15-20 days. Then on 800 mg from the morning and on 400 mg in the afternoon during 6 months.
Inside, 400 mg 2-3 times daily before meals.
The highest daily dose: 1200 mg.
The highest single dose: 400 mg for oral administration and 800 mg for parenteral administration.
Side effects:Nausea.
Allergic reactions.
Overdose:Cases of overdose are not described.
Treatment is symptomatic.
Interaction:Clinically significant interactions are not described.
Special instructions:When there is nausea, it is recommended to lower the dose.